- Bausch Health Companies ( NYSE: BHC ) said its new topical therapy Arazlo for acne vulgaris is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, and the federal government's Non-Insured Health Benefits (NIHB) drug plan, which serves Canada's First Nations and Inuit populations.
- The company noted that Arazlo is the first tazarotene lotion therapy approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.
- Bausch added that the listings by the four public drug plans are the first for Arazlo in Canada, with others expected to follow due to successful conclusion of listing negotiations with the pan-Canadian Pharmaceutical Alliance, representing the drug plans of the federal government and all provinces and territories.
For further details see:
Bausch Health acne lotion Arazlo available in Canada under public drug plans